BIOMAT Database Logo BIOMAT Database Logo

A double-blind comparative study of remoxipride and haloperidol in schizophrenic and schizophreniform disorders. 1990

J Mendlewicz, and E de Bleeker, and P Cosyns, and G Deleu, and F Lotstra, and A Masson, and C Mertens, and M Parent, and J Peuskens, and E Suy
Hospital Erasme, University Clinics of Brussels, Belgium.

The antipsychotic effect of remoxipride was compared to that of haloperidol in a randomized double-blind study with parallel group design comprising 98 patients with schizophrenia or schizophreniform disorder according to DSM-III. After a 3-7 day placebo washout period, patients received either 150-600 mg of remoxipride or 5-20 mg of haloperidol daily for 6 weeks. No significant differences in efficacy were found between the two treatments. Treatment-emergent checklist symptoms such as hypokinesia, rigidity, and tremor occurred more frequently and were more severe during haloperidol than during remoxipride treatment despite a significantly higher concurrent use of anticholinergic drugs in the haloperidol group. Haloperidol-treated patients reported greater increases in sleep and salivation than remoxipride-treated patients. Shoulder shaking and tremor were reported as occurring more frequently in the haloperidol group according to the Simpson and Angus rating scale for extrapyramidal symptoms. In summary, the two drugs seemed to be equally efficacious, though the tolerability profile favoured remoxipride.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009460 Neurologic Examination Assessment of sensory and motor responses and reflexes that is used to determine impairment of the nervous system. Examination, Neurologic,Neurological Examination,Examination, Neurological,Examinations, Neurologic,Examinations, Neurological,Neurologic Examinations,Neurological Examinations
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D011618 Psychotic Disorders Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994) Psychoses,Psychosis, Brief Reactive,Schizoaffective Disorder,Schizophreniform Disorders,Psychosis,Brief Reactive Psychoses,Brief Reactive Psychosis,Disorder, Psychotic,Disorder, Schizoaffective,Disorder, Schizophreniform,Disorders, Psychotic,Disorders, Schizoaffective,Disorders, Schizophreniform,Psychoses, Brief Reactive,Psychotic Disorder,Reactive Psychoses, Brief,Reactive Psychosis, Brief,Schizoaffective Disorders,Schizophreniform Disorder
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006220 Haloperidol A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) Haldol
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

J Mendlewicz, and E de Bleeker, and P Cosyns, and G Deleu, and F Lotstra, and A Masson, and C Mertens, and M Parent, and J Peuskens, and E Suy
Double blind comparative study of remoxipride and haloperidol in acute schizophrenic patients.
January 1990, Psychopharmacology,
J Mendlewicz, and E de Bleeker, and P Cosyns, and G Deleu, and F Lotstra, and A Masson, and C Mertens, and M Parent, and J Peuskens, and E Suy
A double-blind comparative multicentre study of remoxipride and haloperidol in schizophrenia.
January 1990, Acta psychiatrica Scandinavica. Supplementum,
J Mendlewicz, and E de Bleeker, and P Cosyns, and G Deleu, and F Lotstra, and A Masson, and C Mertens, and M Parent, and J Peuskens, and E Suy
A double blind comparative multicentre study of remoxipride and haloperidol in schizophrenia.
January 1990, Acta psychiatrica Scandinavica. Supplementum,
J Mendlewicz, and E de Bleeker, and P Cosyns, and G Deleu, and F Lotstra, and A Masson, and C Mertens, and M Parent, and J Peuskens, and E Suy
A double-blind comparative study of remoxipride and haloperidol in acute schizophrenia.
January 1990, Acta psychiatrica Scandinavica. Supplementum,
J Mendlewicz, and E de Bleeker, and P Cosyns, and G Deleu, and F Lotstra, and A Masson, and C Mertens, and M Parent, and J Peuskens, and E Suy
A double-blind comparative multicentre study of controlled-release remoxipride, immediate-release remoxipride and haloperidol in schizophrenia.
September 1991, Pharmacopsychiatry,
J Mendlewicz, and E de Bleeker, and P Cosyns, and G Deleu, and F Lotstra, and A Masson, and C Mertens, and M Parent, and J Peuskens, and E Suy
Atypical neuroleptics in acute schizophrenia: a double-blind comparative study of remoxipride and haloperidol.
January 1990, Psychopharmacology bulletin,
J Mendlewicz, and E de Bleeker, and P Cosyns, and G Deleu, and F Lotstra, and A Masson, and C Mertens, and M Parent, and J Peuskens, and E Suy
Remoxipride and haloperidol in schizophrenia: a double-blind multicentre study.
January 1990, Acta psychiatrica Scandinavica. Supplementum,
J Mendlewicz, and E de Bleeker, and P Cosyns, and G Deleu, and F Lotstra, and A Masson, and C Mertens, and M Parent, and J Peuskens, and E Suy
A double-blind multicentre study comparing remoxipride, controlled release formulation, with haloperidol in schizophrenia.
January 1990, Acta psychiatrica Scandinavica. Supplementum,
J Mendlewicz, and E de Bleeker, and P Cosyns, and G Deleu, and F Lotstra, and A Masson, and C Mertens, and M Parent, and J Peuskens, and E Suy
Remoxipride and haloperidol in the acute phase of schizophrenia: a double-blind comparison.
January 1990, Acta psychiatrica Scandinavica. Supplementum,
J Mendlewicz, and E de Bleeker, and P Cosyns, and G Deleu, and F Lotstra, and A Masson, and C Mertens, and M Parent, and J Peuskens, and E Suy
[Schizophreniform disorder: a comparative study of the active phases of schizophrenic disorders].
January 1989, Actas luso-espanolas de neurologia, psiquiatria y ciencias afines,
Copied contents to your clipboard!